SavedAdd your journal

Journals / Eskisehir Medical Journal / 2026 / Volume: 7 Issue: 1

The Role of First-Trimester Nuchal Translucency MoM Values in Predicting Pregnancy Complications and Perinatal Outcomes: A Retrospective Cohort Study

İlk Trimester Nuchal Translucency MoM Değerlerinin Gebelik Komplikasyonları ve Perinatal Sonuçları Öngörmedeki Rolü: Retrospektif Kohort Çalışma

Mustafa Koçar(Kütahya Şehir Hastanesi)0000-0002-6466-6050
Onur Burak Çeğilli(Simav Doç. Dr. İsmail Karakuyu Devlet Hastanesi)0000-0002-6308-5836
Pages
—
Publication Date
2026-02-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Combined assessment of these parameters could facilitate early identification of high-risk pregnancies in low-resource settings.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To evaluate the predictive value of first-trimester nuchal translucency (NT) and pregnancy-associated plasma protein-A (PAPP-A) MoM levels for pregnancy complications and perinatal outcomes, and to assess their clinical utility in a district hospital lacking tertiary neonatal intensive care facilities.
📊
Key Findings & Data:Methods: This retrospective cohort study included 422 singleton pregnancies that underwent first-trimester combined testing at Simav State Hospital between May 2021 and September 2025.
💡
Conclusion & Impact:Combined assessment of these parameters could facilitate early identification of high-risk pregnancies in low-resource settings.
🔬Design:Research Article
📍Scope:2021 Verileri
⚙️Variables:Nuchal translucency · PAPP-A · neonatal intensive care

Abstract

Introduction: To evaluate the predictive value of first-trimester nuchal translucency (NT) and pregnancy-associated plasma protein-A (PAPP-A) MoM levels for pregnancy complications and perinatal outcomes, and to assess their clinical utility in a district hospital lacking tertiary neonatal intensive care facilities. Methods: This retrospective cohort study included 422 singleton pregnancies that underwent first-trimester combined testing at Simav State Hospital between May 2021 and September 2025. Multiple pregnancies, fetal anomalies, major maternal diseases, and incomplete data were excluded. NT, PAPP-A, and free β-hCG values were expressed as multiples of the median (MoM). Outcomes included birthweight, neonatal intensive care unit (NICU) admission, and tertiary referral. ROC curve analysis, Youden index, and multivariate logistic regression were performed. Results: Mean NT, PAPP-A, and β-hCG MoM values were 1.05 ± 0.27, 0.88 ± 0.31, and 1.17 ± 0.42, respectively. NICU admission was significantly higher in pregnancies with NT >1.5 MoM (26.4% vs 9.2%; p < 0.01). Low PAPP-A (<0.5 MoM) was associated with tertiary referral (OR=2.91; 95% CI:1.12–7.54; p=0.028). β-hCG levels showed no significant association. Conclusion: First-trimester NT and PAPP-A MoM levels may help predict non-chromosomal adverse pregnancy outcomes. Combined assessment of these parameters could facilitate early identification of high-risk pregnancies in low-resource settings.

Özet

Giriş: Bu çalışmanın amacı, ilk trimesterde ölçülen nuchal translucency (NT) ve pregnancy-associated plasma protein-A (PAPP-A) MoM değerlerinin gebelik komplikasyonları ve perinatal sonuçları öngörmedeki rolünü değerlendirmek ve özellikle üçüncü basamak yenidoğan yoğun bakım olanağı bulunmayan bir ilçe hastanesi popülasyonunda bu parametrelerin klinik uygulanabilirliğini incelemektir. Yöntemler: Mayıs 2021–Eylül 2025 tarihleri arasında Simav Devlet Hastanesi’nde ikili test yapılan 761 tekil gebelik retrospektif olarak incelendi. Çoğul gebelikler, fetal anomali, majör maternal hastalık ve eksik verili olgular dışlandı; 422 olgu analiz edildi. NT, PAPP-A ve free β-hCG değerleri MoM olarak kaydedildi. Doğum kilosu, yenidoğan yoğun bakım (YYBÜ) yatışı ve üçüncü basamak sevk gereksinimi değerlendirildi. ROC eğrisi, Youden indeksi ve çok değişkenli lojistik regresyon kullanıldı. Bulgular: Ortalama NT, PAPP-A ve β-hCG MoM değerleri sırasıyla 1.05 ± 0.27, 0.88 ± 0.31 ve 1.17 ± 0.42 idi. NT >1.5 MoM olan olgularda YYBÜ yatış oranı yüksekti (%26.4 vs %9.2; p < 0.01). Düşük PAPP-A (<0.5 MoM) düzeyi üçüncü basamak sevk gereksinimiyle ilişkiliydi (OR=2.91; %95 GA:1.12–7.54; p=0.028). β-hCG ile anlamlı ilişki saptanmadı. Sonuç: İlk trimester NT ve PAPP-A MoM değerleri, kromozomal anomali dışı olumsuz gebelik sonuçlarını öngörmede yararlı olabilir. Bu parametrelerin birlikte değerlendirilmesi, sınırlı kaynaklı merkezlerde riskli gebeliklerin erken tanımlanmasını kolaylaştırabilir.

🔖

Cite This Article

Koçar, M., Çeğilli, O. B. (2026). The Role of First-Trimester Nuchal Translucency MoM Values in Predicting Pregnancy Complications and Perinatal Outcomes: A Retrospective Cohort Study. Eskisehir Medical Journal, Volume: 7 Issue: 1. https://doi.org/10.48176/esmj.2026.242

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bet BB, Lugthart MA, Linskens IH, et al. Adverse pregnancy outcome in fetuses with early increased nuchal translucency: prospective cohort study. Ultrasound Obstet Gynecol. 2024;64(2):164–172. doi:10.1002/uog.27623
  2. Tiyatha S, Sirilert S, Sekararithi R, Tongsong T. Association between unexplained thickened nuchal translucency and adverse pregnancy outcomes. Arch Gynecol Obstet. 2018;298(1):97–101. doi:10.1007/s00404-018-4790-9
  3. Bilardo CM, Müller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol. 2007;30(1):11–18. doi:10.1002/uog.4044.
  4. Monget P, Oxvig C. PAPP-A and the IGF system. Ann Endocrinol (Paris). 2016;77(2):90–96. doi:10.1016/j.ando.2016.04.015.
  5. Kavak N, Basgul A, Elter K, Uygur M, Goksalan H. The efficacy of first-trimester PAPP-A and free β-hCG levels for predicting adverse pregnancy outcome. J Perinat Med. 2006;34(2):145–148. doi:10.1515/JPM.2006.026.
  6. Clur SA, Ottenkamp J, Bilardo CM. The nuchal translucency and the fetal heart: a literature review. Prenat Diagn. 2009;29(8):739–748. doi:10.1002/pd.2281.
  7. Masihi S, Amirgholami B, Nourian B, Behbahani SZ, Khezri M, Javid F. Association of first-trimester low PAPP-A levels (<0.2 MoM) with maternal and fetal outcomes. Eur J Med Health Sci. 2025;7(1):10–14. doi:10.24018/ejmed.2025.7.1.2233.
  8. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. doi:10.1016/j.ajog.2010.08.009.
  9. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-β-hCG concentrations and nuchal translucency are associated with obstetric complications: the FASTER Trial. Am J Obstet Gynecol. 2004;191(4):1446–1451. doi:10.1016/j.ajog.2004.06.052.
  10. Souka AP, Krampl E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol. 2001;18(1):9–17. doi:10.1046/j.1469-0705.2001.00454.x.
  11. Özdemir Ö, Aslan H. The efficacy of first trimester maternal PAPP-A and free β-hCG levels in predicting adverse pregnancy outcomes. İKSSTD. 2022;14(3):237–244. doi:10.14744/iksstd.2022.79026.
  12. van Ravenswaaij R, Tesselaar-van der Goot M, de Wolf S, van Leeuwen-Spruijt M, Visser GHA, Schielen PCJI. First-trimester serum PAPP-A and fβ-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome. Prenat Diagn. 2011;31(1):50–57. doi:10.1002/pd.2610.
  13. Bianchi B, Zaccaria G, Kang X, Cos T, Tsepelidis S, Carlin A, Jani JC, Badr DA. Pregnancy outcomes in patients with increased nuchal translucency using non-invasive prenatal testing and first trimester ultrasound. Eur J Obstet Gynecol Reprod Biol. 2025;313:114572. doi:10.1016/j.ejogrb.2025.114572.
  14. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8–15. doi:10.1159/000341264.